Indrayani Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/06/2025 ,inter alia, to consider and approve audited financial results ....

Net loss reportedEBITDA margin compressionNegative operating cash flowDebt to equity above the thresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹16.50

prior close

₹16.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-0.3% vs market

Other Agricultural Products peers, median of 53sector+0.0%+0.0% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and in line with its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.3-0.3+0.0+0.0

Next day

-1.5+0.7-2.2-0.7-0.9

-2.7+1.0-3.7-1.1-1.7

-3.0+1.1-4.1-0.6-2.4

-3.2+0.8-4.0-2.5-0.7

-1.5+1.3-2.8-2.3+0.8

-3.9+1.7-5.7-0.6-3.3

15d

-8.9+1.5-10.4-2.3-6.6

-15.1+4.0-19.1-1.4-13.7

-10.3+1.8-12.1-7.1-3.2

-29.7-1.0-28.7-9.5-20.2

UpDownMarket · Nifty Microcap 250Sector · Other Agricultural Products peers, median of 53Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indrayani Biotech Limited has informed BSE that its Board meeting to consider and approve the audited financial results (standalone and consolidated) for Q4 and the financial year ended 31st March 2025 has been rescheduled to 9th June 2025. The original deadline for submission was 30th May 2025 as per SEBI's Listing Regulations. The company has cited administrative delays, specifically the consolidation of results from subsidiaries and the completion of internal and external audit processes, as the reasons for the delay. The trading window for designated persons will remain closed until 48 hours after the declaration of results.

Likely market impact

While the delay is attributed to procedural and audit-related reasons rather than business issues, late submission of audited results may raise minor governance and compliance concerns among investors. Shareholders should watch the 9th June announcement closely for actual financial performance details.

By the numbersConsolidated · Q4 FY25 vs Q4 FY24

	Q4 FY25	Q4 FY24	Change
Revenue	₹50.57 Cr	₹44.38 Cr	+13.9%
Operating profit	−₹11.10 Cr	₹3.70 Cr	−399.9%
Profit after tax	−₹8.53 Cr	₹4.73 Cr	−280.1%
EBITDA margin	-11.3%	22.9%	−34.3 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.